株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌治療向けPARP阻害薬市場:価格・投薬量・臨床パイプラインの展望

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023

発行 KuicK Research 商品コード 628063
出版日 ページ情報 英文 200 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

癌治療向けPARP阻害薬市場:価格・投薬量・臨床パイプラインの展望 Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023
出版日: 2018年04月20日 ページ情報: 英文 200 Pages
概要

当レポートでは、世界のPARP阻害薬市場市場について調査し、市場の現況、動向、ダイナミクス、および市場に影響を及ぼす近年の進歩について詳細に分析しており、治療薬の価格・売上・患者1人あたりの治療コスト、市場の将来予測などについてまとめています。

第1章 ポリ (ADPリボース) ポリメラーゼ阻害薬のイントロダクション

  • ユニークな癌治療薬としてのPARP阻害薬
  • PARP阻害薬の進化的な側面
  • PARPタンパク質 & 阻害薬の準備段階

第2章 PARPタンパク質:癌治療薬の開発にとって魅力的な標的

  • PARP阻害薬の標的部位の構造機構
  • PARP阻害薬の構造機構

第3章 正常細胞・癌細胞におけるPARPの役割の治療的開発

  • 正常細胞におけるPARPタンパク質の重要性
  • 腫瘍形成におけるPARPタンパク質の重要性:細胞分裂・DNA修復への影響
  • PARP阻害薬:癌細胞を除去する注目すべき作用機序

第4章 世界のポリ (ADPリボース) ポリメラーゼ阻害薬の臨床パイプライン概要

第5章 癌の単剤療法としての市販ポリ (ADPリボース) ポリメラーゼ阻害薬 (PARP阻害薬)

  • Olaparib
  • Rucaparib
  • Niraparib
  • 臨床パイプラインにおける有望なPARP阻害薬:有効性・投薬量・予想価格

第6章 世界の癌治療向けPARP阻害薬:市場の現況

  • PARP阻害薬市場の概要
  • 市場区分:特許
  • 市場区分:医薬品売上
  • 市場動向

第7章 従来の癌治療によるPARP阻害薬:有効性・投薬量・価格の分析

  • 化学療法によるPARP阻害薬
  • 放射線療法との組み合せにおけるPARP阻害薬

第8章 最新の癌治療によるPARP阻害薬の有効性の改善

  • PARP阻害薬・標的療法の組み合せ
  • 免疫療法との組み合せにおけるPARP阻害薬

第9章 世界のPARP阻害薬市場を促進する要因

  • いくつかのPARP阻害薬の連続承認・近い将来に見込まれる承認
  • 強力な臨床パイプライン
  • 大きな患者ベース
  • 認可済みPARP阻害薬の商業的な成功

第10章 世界のPARP阻害薬市場における課題

  • 科学の限界・副作用の数
  • 面倒な承認プロセス

第11章 世界のPARP阻害薬市場における将来予測

  • パイプラインにおけるPARP阻害薬

第12章 世界の世界のPARP阻害薬の臨床パイプライン:企業・適応症・フェーズ別

  • 前臨床
  • 臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第13章 上市済み癌治療向けPARP阻害薬の臨床考察:企業・症状別

  • Olaparib (Lynparza)
  • Niraparib (Zejula)
  • Rucaparib (Rubraca)

第14章 競合環境

  • 2X Oncology
  • Abott Laboratories
  • Cephalon
  • Checkpoint Therapeutics
  • エーザイ
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals
  • KuDOS Pharmaceuticals
  • 協和発酵キリン
  • Lead Therapeutics
  • Shanghai De Novo Pharmatech
目次

Report highlights:

  • Current Market Trends & Development Scenario
  • Drug Availability, Dosage & Treatment Schedule
  • Commercially Available Drugs Price Analysis
  • Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs
  • Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs
  • Market Segmentation by Drug Patent & Deals

Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much more innovative approach, collectively known as targeted therapies. Targeted cancer therapy segment currently flourishes with several types of therapeutics among which PARP inhibitors have gained immense popularity due to their superior efficacy to conventional therapeutics.

Inhibitors include drugs or substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. PARP inhibitors are recent entrants in the targeted therapy segment which have gained worldwide popularity as the most common type treatment in certain clinical indications like ovarian cancer and breast cancer.

Poly-ADP Ribose Polymerase or PARP are special proteins that play a key role in assisting damaged cells to repair themselves. The initial clinical testing of PARP inhibitors began nearly a decade ago, following the discovery that these agents in vitro had heightened anticancer activity in cancer cells that harbored BRCA mutations compared to BRCA wild-type cancer cells with intact DNA repair.

Research proved that fault in either of BRCA 1 and BRCA 2 genes have an increased risk of certain types of cancer such as breast cancer, ovarian cancer and prostate cancer. Cells are less likely to repair themselves if there is a fault in one or both of these genes. Blocking PARP with a PARP inhibitor showed impressive results in preventing the proliferation of cancer cells by interfering with their DNA repair mechanism and killing them, thus resulting in a therapeutic outcome.

Currently, there are 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016 and Niraparib in 2017.

Trends show that the cancer therapy market is steadily shifting from conventional therapeutics to modern therapeutics due to their better safety, efficacy and specificity; thus creating an excellent opportunity for promising therapeutics like PARP inhibitors.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US$ 109 Million during first nine months of commercial launch. Rucaparib - the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

KuicK Research Analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

Table of Contents

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors

  • 1.1 PARP Inhibitors as Unique Cancer Therapy
  • 1.2 Evolutionary Aspects of PARP Inhibitors
  • 1.3 Prelude to PARP Proteins & their Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics

  • 2.1 Structural Organization of Target Site of PARP Inhibitors
  • 2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells

  • 3.1 Significance of PARP Proteins in Normal Cells
  • 3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
  • 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview

5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy

  • 5.1 Olaparib
    • 5.1.1 Availability, Dosage & Treatment Schedule
    • 5.1.2 Price Analaysis
  • 5.2 Rucaparib
    • 5.2.1 Availability, Dosage & Treatment Schedule
    • 5.2.2 Price Analysis
  • 5.3 Niraparib
    • 5.3.1 Availability, Dosage & Treatment Schedule
    • 5.3.2 Price Analysis
  • 5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
    • 5.4.1 Talazoparib
    • 5.4.2 Veliparib

6. Global PARP Inhibitor Cancer Therapy Current Market Scenario

  • 6.1 PARP Inhibitor Market Outline
  • 6.2 Market Segmentation by Patent
  • 6.3 Market Segmentation by Drug Sales
  • 6.4 Market Trends

7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis

  • 7.1 PARP Inhibitors with Chemotherapy
    • 7.1.1 Temozolomide
    • 7.1.2 Platinum Salts
    • 7.1.3 Taxanes
    • 7.1.4 Gemcitabine
    • 7.1.5 Topoisomerase Inhibitors/Poisons
  • 7.2 PARP Inhibitors in Combination with Radiotherapy

8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies

  • 8.1 Combination of PARP Inhibitors & Targeted Therapies
    • 8.1.1 PARP Inhibitors with EGFR Inhibitors
    • 8.1.2 PARP Inhibitors with VEGFR Inhibitors
    • 8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
    • 8.1.4 PARP Inhibitors with Trastuzumab
    • 8.1.5 Anti-endocrine agents
    • 8.1.6 HSP90 Inhibitors
    • 8.1.7 IGF-1R & HDAC Inhibitors
  • 8.2 PARP Inhibitors in Combination with Immunotherapies

9. Factors Driving Global PARP Inhibitors Market

  • 9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
  • 9.2 Strong clinical Pipeline
  • 9.3 Large Patient Base
  • 9.4 Commercial Success of Approved PARP Inhibitors

10. Global PARP Inhibitor Market Challenges

  • 10.1 Scientific Limitations and the Number of Side Effects
  • 10.2 Tedious approval process

11. Global PARP Inhibitors Market Future Forecast

  • 11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer
    • 11.1.1 PARP Inhibitors for Prostate Cancer
    • 11.1.2 PARP Inhibitors for Lung Cancer
    • 11.1.3 PARP Inhibitors in Pancreatic Cancer
    • 11.2 Market Opportunity

12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1 Preclinical
  • 12.2 Clinical
  • 12.3 Phase-I
  • 12.4 Phase-I/II
  • 12.5 Phase-II
  • 12.6 Phase-III

13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication

  • 13.1 Olaparib (Lynparza)
  • 13.2 Niraparib (Zejula)
  • 13.3 Rucaparib (Rubraca)

14. Competitive Landscape

  • 14.1 2X Oncology
  • 14.2 Abott Laboratories
  • 14.3 Cephalon
  • 14.4 Checkpoint Therapeutics
  • 14.5 Eisai Co. Ltd
  • 14.6 IMPACT Therapeutics
  • 14.7 Jeil Pharmaceuticals
  • 14.8 KuDOS Pharmaceuticals
  • 14.9 Kyowa Hakko Kirin
  • 14.10 Lead Therapeutics
  • 14.11 Shanghai De Novo Pharmatech

List of Figures

  • Figure 1-1: History & Evolution of PARP Inhibitors
  • Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
  • Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
  • Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
  • Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
  • Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
  • Figure 4-1: Global - Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023
  • Figure 4-2: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 4-3: Global - Cancer PARP Inhibitors Pipeline by Phase (%),2018 till 2023
  • Figure 4-4: Global - Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
  • Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months
  • Figure 5-2: Olaparib - Available Concentrations (mg), 2018
  • Figure 5-3: Olaparib - Dosage Analysis (mg/Day)
  • Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)
  • Figure 5-6: Olaparib - Price Analysis by Type (US$/Unit), 2018
  • Figure 5-7: Olaparib - Price Analysis by Type (US$/Packet), 2018
  • Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)
  • Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018
  • Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
  • Figure 5-15: Rucaparib - Price Analysis (US$), 2018
  • Figure 5-16: Rucaparib - Average Price Analysis for Reoccurent BRCA Mutated Cancer Treatment (US$), 2018
  • Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
  • Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-19: Niraparib - Dosage Analysis (mg/Day)
  • Figure 5-20: Niraparib - Price Analysis (US$), 2018
  • Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
  • Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US$), 2018
  • Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis
  • Figure 5-25: Talazoparib - Upcoming Concentration (mg), 2018
  • Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US$), 2018
  • Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials
  • Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)
  • Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)
  • Figure 6-1: Global - Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018
  • Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018
  • Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018
  • Figure 6-4: Global - Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018
  • Figure 6-5: Global - Rubraca (Rucaparib) Patent Aprroval & Expiration Year, 2018
  • Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018
  • Figure 6-7: Global - Zejula (Niraparib) Patent Approval & Expiration Year, 2018
  • Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018
  • Figure 6-9: Global - Lynparza (Olaparib) Sales (US$ Million), 2015-2017
  • Figure 6-10: Global - Rubraca (Rucaparib) Sales (US$ Milion), 2017
  • Figure 6-11: Global - Zejula (Niraparib) Sales (US$ Million), Q1'2017 & Q2'2017
  • Figure 6-12: Global - PARP Inhibitors End Users (Number of Patients/Year), 2018
  • Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
  • Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
  • Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
  • Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
  • Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)
  • Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
  • Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)
  • Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)
  • Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018
  • Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)
  • Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future
  • Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment
  • Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment

List of Tables

  • Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer